2016-117 – Mayo Clinic has discovered that the use of USP7 inhibitors sensitize HER2+breast cancer cells to existing HER2+ therapies.
Therapeutic Modulation of the MoCo Biosynthesis Pathway to Protect Neurons and Axons from Inflammation-Induced Injury
2014-299 – Mayo Clinic has developed an innovative therapeutic strategy to use molybdenum cofactor (MoCo) to treat neurological inflammatory disease.
2010-312 – The invention relates to the treatment of meningiomas using a composition including a cytotoxic agent and a compound selected from phenylbenzothiazole derivatives, stilbene derivatives, and biphenylalkyne derivatives.
2007-163 – The invention is a series of compounds that block the human transporters for serotonin (hSERT), norepinephrine (hNET), and dopamine (hDAT). Compounds of this series are “triple re-uptake inhibitors” that can be grouped as follows based on their rank-order of potency and affinity at the 3 transporters: 1) potent antagonist of hSERT, hNET, and hDAT with affinity rankings of hSERT (greater than... Read More
2000-090 – Novel small molecule compounds that selectively inhibit norepinephrine, serotonin and dopamine reuptake have been developed. Specifically, the invention provides amine compounds, methods for synthesizing amine compounds, and methods for inhibiting neurotransmitter reuptake. The amine compounds provided herein can be used as potent, wide-spectrum antidepressant medications for inhibiting... Read More
2013-105 – The ε4 allele of the apolipoprotein E (APOE) gene is the strongest genetic risk factor for late-onset Alzheimer’s disease (AD) compared to the more common ε3 allele. Studies in animal models and humans suggest that apoE4 exhibits both loss-of-function and gain-of-toxic-function compared to apoE3. In regulating amyloid pathology, apoE4 is less efficient than apoE3 in mediating the clearance of... Read More
2012-112 – We have identified abnormalities in the B cell compartment in the circulation of patients with ALS. This abnormality could be used to develop a test to measure the prognosis of patients with ALS or to diagnose patients with different forms of the disease. Additionally, the involvement of B cells in the pathology of ALS will lead treatments that may ameliorate the disease or its symptoms.
2012-098 – Agelastatin A (AA) is an anti-neoplastic agent with anti-osteopontin (OPN) activity. Brain tumors often express OPN significantly. A comprehensive chemoinformatic analysis followed by in vivo pharmacokinetic evaluations in mice is performed. CNS penetration of AA is about 10%. AA should be further tested for activity against brain tumors.
2012-004 – What is envisioned is a system of electrochemical and electrical monitoring coupled with directed stimulation to bypass damaged nerve tissue. The combination of information detection, conversion algorithm and programmed stimulation will provide regeneration of the neural commands. Further it is envisioned that a pump can be added to provide neural modular/growth factors to maintain the nerve... Read More
2011-042 – DNA Aptamers Promoting Remyelination in Neurodegenerative Disease Single-stranded DNA aptamers 40 nucleotides in length were selected for binding to mouse myelin and were evaluated for their ability to promote remyelination. This approach was based upon previous reports indicating that IgM antibodies are capable of promoting remyelination in animal models of multiple sclerosis. After... Read More
Transpulmonary Induction of Therapeutic Hypothermia (In Collaboration with Minnesota High-Tech Resources LLC)
2010-284 – Therapeutic hypothermia is a widely accepted methodology for mitigating injury to vital organs following ischemic insults. Cellular metabolism decreases with lower temperatures and this reduction in metabolism protects metabolically active organs including the heart and brain during episodes of ischemia and hypoxia. Therapeutic hypothermia is currently practiced in association with a number... Read More
Aquaporin-4-Binding Autoantibodies in Patients with Neuromyelitis Optica Impair Glutamate Transport by Down-Regulating EAAT2
2008-303 – Materials and Methods for Treating Neuromyelitis Optics (NMO) Methods for treating NMO are claimed including the use of glulamate receptor antagonists and/or compounds that inhibit complement.
2006-224 – This is to provide knowledge about the use of neurotensin receptor agonists for treatment of various medical problems, including acute and chronic pain due to various causes and abuse of various types of psychostimulants (such as nicotine, cocaine, and amphetamines).
2006-154 – To increase progranulin in animals, progranulin levels and biologically active fragments of progranulin can be elevated in animals by direct administration of the protein or its fragments, either in the presence or absence of agents that stabilize the biological activity. Routes of delivery include, but are not limited to, intranasal, oral, inhalation, intracerebro-ventricular injection,... Read More
2003-149 – Technology Description Compositions and methods have been developed for detecting plaques and treating CNS disorders. Polyamine modification of amyloid beta peptides or antibodies binding to amyloid beta increases blood-brain barrier (BBB) permeability and incorporation of a contrast agent permits MRI detection of plaque deposits. A novel peptide-based imaging agent has also been developed... Read More
2001-127 – Technology Description Compositions and methods have been developed for detecting plaques and treating CNS disorders. Polyamine modification of amyloid beta peptides or antibodies binding to amyloid beta increases blood-brain barrier (BBB) permeability and incorporation of a contrast agent permits MRI detection of plaque deposits. A novel peptide-based imaging agent has also been developed... Read More